--- title: "BioAffinity Soars On Strong Preliminary Sales Growth Of CyPath Lung Test" type: "News" locale: "en" url: "https://longbridge.com/en/news/281382391.md" description: "Shares of bioAffinity Technologies Inc. (BIAF) surged over 10% after the company reported a 146% year-over-year increase in unit sales of its CyPath Lung test for Q1 2026, surpassing expectations. The noninvasive test aids in early lung cancer detection and is gaining traction among physicians. The stock is currently trading at $4.21 following a 1-for-30 reverse stock split implemented in September 2025." datetime: "2026-04-01T13:57:24.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281382391.md) - [en](https://longbridge.com/en/news/281382391.md) - [zh-HK](https://longbridge.com/zh-HK/news/281382391.md) --- # BioAffinity Soars On Strong Preliminary Sales Growth Of CyPath Lung Test Add as your preferred news source on Google Add Now Shares of bioAffinity Technologies Inc. (BIAF) are up over 10% in Wednesday's trading, after the company announced stronger-than-expected unit growth in the first quarter of 2026 for its noninvasive diagnostic test, CyPath Lung. CyPath Lung is a noninvasive test to improve the early detection of lung cancer in patients at high risk for the disease. It can be used alone or in combination with other diagnostic tools. This test supports lung cancer risk assessment, pulmonary nodule management and post-treatment surveillance. According to the company, based on preliminary unaudited data, the unit sales of CyPath Lung increased 146% year-over-year in the first quarter of 2026, significantly exceeding internal expectations. bioAffinity Technologies attributed the strong performance to accelerating physician adoption and expanding clinical utilization of the diagnostic test, which combines flow cytometry and AI to improve lung cancer risk assessment and nodule management. BIAF has traded in a range of $0.69 to $32.10 in the last 1 year. A 1-for-30 reverse stock split was implemented on September 19, 2025. The stock is currently trading at $4.21, up 10%. For comments and feedback contact: editorial@rttnews.com Business News ### Related Stocks - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BIAF.US](https://longbridge.com/en/quote/BIAF.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BIAFW.US](https://longbridge.com/en/quote/BIAFW.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) ## Related News & Research - [Pulse Biosciences Reports Strong nPulse Atrial Fibrillation Data](https://longbridge.com/en/news/284232599.md) - [Alma Unveils Longevity Approach at Alma Academy, Advancing Long-Term Skin Performance](https://longbridge.com/en/news/284398166.md) - [03:17 ET3Shape Receives FDA 510(k) Clearance for 3Shape Dx Software](https://longbridge.com/en/news/284331015.md) - [bioAffinity Showcases CyPath Lung Test at Cleveland Clinic](https://longbridge.com/en/news/281888908.md) - [12:12 ETKROMATID to Present Breakthrough Genomic Integrity Benchmarking at ASGCT 2026, Powering the World's First Genomic Intelligence Platform](https://longbridge.com/en/news/284807394.md)